CLINICAL_TRIALS
ClinicalTrials.gov record update
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT05431582
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-28T10:39:06.754670+00:00
- Published At
- 2023-06-15T00:00:00+00:00
- Record Updated At
- 2023-06-15
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Tumors", "Ovarian Cancer", "Breast Cancer", "Lung Cancer", "Pancreatic Cancer"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2023-06-15"- protocolSection.identificationModule.nctId
"NCT05431582"- protocolSection.identificationModule.officialTitle
"Phase I Study of ZN-c3 and Bevacizumab \u00b1 Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors"- protocolSection.statusModule.overallStatus
"WITHDRAWN"- protocolSection.designModule.phases
["PHASE1"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.